During the past decade, MNJ Institute of Oncology & Regional Cancer Center conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MNJ Institute of Oncology & Regional Cancer Center" #1 sponsor was "Eli Lilly and Company" with 2 trials, followed by "Ayana Pharma Ltd.," with 1 trials sponsored, "Imugene Limited" with 1 trials sponsored, "Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre" with 1 trials sponsored and "Partha Basu" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MNJ Institute of Oncology & Regional Cancer Center" #1 collaborator was "MNJ Institute of Oncology & Regional cancer Center" with 2 trials as a collaborator, "All India Institute of Medical Sciences, New Delhi" with 1 trials as a collaborator, "BeiGene, Ltd." with 1 trials as a collaborator, "Cancer Foundation of India" with 1 trials as a collaborator and "Christian Fellowship Community Health Centre" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "MNJ Institute of Oncology & Regional Cancer Center" are "Adenocarcinoma" (1 trials), "Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials), "Carcinoma, Squamous Cell" (1 trials) and "Carcinoma, Squamous Cell of Head and Neck" (1 trials). Many other conditions were trialed in "MNJ Institute of Oncology & Regional Cancer Center" in a lesser frequency.

Most popular intervention types in "MNJ Institute of Oncology & Regional Cancer Center" are "Drug" (9 trials), "Biological" (3 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (2 trials), "5-Fluorouracil" (1 trials), "Ascorbic Acid" (1 trials), "Capecitabine" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "MNJ Institute of Oncology & Regional Cancer Center" are 6 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "MNJ Institute of Oncology & Regional Cancer Center". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in MNJ Institute of Oncology & Regional Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MNJ Institute of Oncology & Regional Cancer Center, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".